17.05.2026, 1520 Zeichen

Strabag: After two years of design-and-build preparation, construction group STRABAG, in partnership with Group company ZÜBLIN, was awarded the contract for the structural implementation of several procurement packages for the project ABS Gäubahn Nord / Pfaffensteigtunnel. The scheme is regarded as one of the key infrastructure schemes in the expansion of the Gäubahn rail line in south-west Germany and plays a decisive role in strengthening climate-friendly, future-oriented mobility. The client is DB Projekt Stuttgart–Ulm GmbH.
Strabag: weekly performance: -2.16%

Marinomed: Marinomed Biotech AG, a healthcare-focused innovator committed to improving patient outcomes, announced that Tacrolimus eyedrops are the prime candidate for entering the compounding business based on input from ophthalmologists worldwide. Marinomed expects first revenues in Q4 2026 or beginning of 2027 from partners and fast growth in 2027. Marinomed has gathered extensive feedback from key opinion leaders worldwide in the field of inflammatory ocular surface disease. The experts confirmed significant unmet medical need for Tacrolimus eyedrops in specific indications and for certain patient populations that cannot be adequately addressed by existing therapies. Compounded Tacrolimus eyedrops based on the Marinosolv technology could close this gap and is also an interesting commercial opportunity.
Marinomed Biotech: weekly performance: -8.26%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (11/05/2026)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1185: ATX etwas fester, Big Austrian IPO Day, der Jubilar Andritz geht in die Champions League mit Do&Co

Bildnachweis

Aktien auf dem Radar:AT&S, Strabag, Telekom Austria, Semperit, EuroTeleSites AG, Amag, Uniqa, DO&CO, Lenzing, SBO, voestalpine, Frequentis, Andritz, FACC, Heid AG, Mayr-Melnhof, Rosenbauer, BKS Bank Stamm, CPI Europe AG, Österreichische Post, UBM.

---